Search research articles
Contact Us
Filters
Showing results (1-10 of 34) with videos related to
Page
of 4
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 21, 2019
Reply to Lanzafame et al
Elizabeth A Martin, Carey Hwang, Chloe Orkin
ACS Infectious Diseases
|
October 18, 2019
Rational Design of Doravirine: From Bench to Patients
Carey Hwang, Ming-Tain Lai, Daria Hazuda
Clinical Drug Investigation
|
April 22, 2015
An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects
Marc Bifano, Robert Adamczyk, Carey Hwang, et al.
Antimicrobial Agents and Chemotherapy
|
September 25, 2019
Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarate
Wayne Greaves, Hong Wan, Ka Lai Yee, et al.
Antiviral Therapy
|
December 18, 2013
Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate
Marc Bifano, Heather Sevinsky, Carey Hwang, et al.
Antimicrobial Agents and Chemotherapy
|
April 15, 2015
Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects
Li Zhu, Matthew Hruska, Carey Hwang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 24, 2019
Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis
Chloe Orkin, Jean-Michel Molina, Johan Lombaard, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 26, 2013
Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068
Neelanjana Ray, Carey Hwang, Matthew D Healy, et al.
The Lancet. Gastroenterology & Hepatology
|
June 1, 2025
Standardising HBV nomenclature: a call to action from the HBV Forum
Su Wang, Mitchell Leus, Markus Cornberg, et al.
Emerging Microbes & Infections
|
July 23, 2024
Biotech's role in advancing HIV vaccine development
Roger Tatoud, Christian Brander, Carey Hwang, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 34) with videos related to
Sort By:
Page
of 4
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 21, 2019
Reply to Lanzafame et al
Elizabeth A Martin, Carey Hwang, Chloe Orkin
ACS Infectious Diseases
|
October 18, 2019
Rational Design of Doravirine: From Bench to Patients
Carey Hwang, Ming-Tain Lai, Daria Hazuda
Clinical Drug Investigation
|
April 22, 2015
An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects
Marc Bifano, Robert Adamczyk, Carey Hwang, et al.
Antimicrobial Agents and Chemotherapy
|
September 25, 2019
Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarate
Wayne Greaves, Hong Wan, Ka Lai Yee, et al.
Antiviral Therapy
|
December 18, 2013
Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate
Marc Bifano, Heather Sevinsky, Carey Hwang, et al.
Antimicrobial Agents and Chemotherapy
|
April 15, 2015
Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects
Li Zhu, Matthew Hruska, Carey Hwang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 24, 2019
Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis
Chloe Orkin, Jean-Michel Molina, Johan Lombaard, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 26, 2013
Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068
Neelanjana Ray, Carey Hwang, Matthew D Healy, et al.
The Lancet. Gastroenterology & Hepatology
|
June 1, 2025
Standardising HBV nomenclature: a call to action from the HBV Forum
Su Wang, Mitchell Leus, Markus Cornberg, et al.
Emerging Microbes & Infections
|
July 23, 2024
Biotech's role in advancing HIV vaccine development
Roger Tatoud, Christian Brander, Carey Hwang, et al.
Page
of 4